166 related articles for article (PubMed ID: 38482230)
1. Management and mechanism of calciphylaxis in a patient treated with the FGFR inhibitor pemigatinib-a case report.
Chandana SR; Frisch A; Mendoza S; Sinniah RS; Crysler O; Banga R; Perkins DE
J Gastrointest Oncol; 2024 Feb; 15(1):478-484. PubMed ID: 38482230
[TBL] [Abstract][Full Text] [Related]
2. Calciphylaxis Cutis Associated With Fibroblast Growth Factor Receptor (FGFR) Inhibitor Therapy: A New Challenge.
Griffith P; Jedrych J; Sunshine J; Laheru DA; Yarchoan M
Cureus; 2022 Jan; 14(1):e21478. PubMed ID: 35223258
[TBL] [Abstract][Full Text] [Related]
3. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
Abou-Alfa GK; Sahai V; Hollebecque A; Vaccaro G; Melisi D; Al-Rajabi R; Paulson AS; Borad MJ; Gallinson D; Murphy AG; Oh DY; Dotan E; Catenacci DV; Van Cutsem E; Ji T; Lihou CF; Zhen H; Féliz L; Vogel A
Lancet Oncol; 2020 May; 21(5):671-684. PubMed ID: 32203698
[TBL] [Abstract][Full Text] [Related]
4. Pemigatinib in cholangiocarcinoma with a FGFR2 rearrangement or fusion.
Storandt MH; Jin Z; Mahipal A
Expert Rev Anticancer Ther; 2022 Dec; 22(12):1265-1274. PubMed ID: 36408971
[TBL] [Abstract][Full Text] [Related]
5. Global Expanded Access Program for Pemigatinib in Patients with Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma and Fibroblast Growth Factor Receptor Gene Alterations.
Lindley A; Prager G; Bitzer M; Burn TC; Lihou CF; Croft E
Cancer Res Treat; 2024 Feb; ():. PubMed ID: 38351684
[TBL] [Abstract][Full Text] [Related]
6. Infigratinib for the Treatment of Metastatic or Locally Advanced Cholangiocarcinoma With Known FGFR2 Gene Fusions or Rearrangements.
White K; Anwar AI; Jin K; Bollich V; Kelkar RA; Talbot NC; Klapper RJ; Ahmadzadeh S; Viswanath O; Varrassi G; Shekoohi S; Kaye AD
Cureus; 2023 Oct; 15(10):e46792. PubMed ID: 37954763
[TBL] [Abstract][Full Text] [Related]
7. Hyperphosphatemic Tumoral Calcinosis With Pemigatinib Use.
Puar A; Donegan D; Helft P; Kuhar M; Webster J; Rao M; Econs M
AACE Clin Case Rep; 2022; 8(5):217-220. PubMed ID: 36189136
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacological characteristics and clinical study results of Pemigatinib (Pemazyre
Kabu K; Takei S; Kondo M; Kitazawa K; Harada T
Nihon Yakurigaku Zasshi; 2021; 156(6):392-402. PubMed ID: 34719574
[TBL] [Abstract][Full Text] [Related]
9. Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies.
Parisi A; Delaunay B; Pinterpe G; Hollebecque A; Blanc JF; Bouattour M; Assenat E; Ben Abdelghani M; Sarabi M; Niger M; Vivaldi C; Mandalà M; Palloni A; Bensi M; Garattini SK; Tougeron D; Combe P; Salati M; Rimini M; Cella CA; Tucci M; Diana A; Mori E; Longarini R; Artru P; Roth G; Evesque L; Vienne A; Turpin A; Hiret S; Bourgeois V; Herve C; Paulon R; Stacoffe M; Malka D; Neuzillet C; Edeline J; Lievre A; Guimbaud R; Chapda MCP; Rimassa L; Giampieri R; Valle J; Berardi R; Fares N
Eur J Cancer; 2024 Mar; 200():113587. PubMed ID: 38340384
[TBL] [Abstract][Full Text] [Related]
10. A drug safety evaluation of pemigatinib for advanced cholangiocarcinoma.
Uson PLS; Bearss J; Babiker HM; Borad M
Expert Opin Drug Saf; 2023; 22(8):637-641. PubMed ID: 37363820
[TBL] [Abstract][Full Text] [Related]
11. Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma.
Rizzo A; Ricci AD; Brandi G
Cancer Treat Res Commun; 2021; 27():100337. PubMed ID: 33611090
[TBL] [Abstract][Full Text] [Related]
12. Targeting FGFRs Using PD173074 as a Novel Therapeutic Strategy in Cholangiocarcinoma.
Balasubramanian B; Yacqub-Usman K; Venkatraman S; Myint KZ; Juengsamarn J; Sarkhampee P; Lertsawatvicha N; Sripa J; Kuakpaetoon T; Suriyonplengsaeng C; Wongprasert K; Grabowska AM; Bates DO; Janvilisri T; Tohtong R
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173994
[TBL] [Abstract][Full Text] [Related]
13. Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study.
Shi GM; Huang XY; Wen TF; Song TQ; Kuang M; Mou HB; Bao LQ; Zhao HT; Zhao H; Feng XL; Zhang BX; Peng T; Zhang YB; Li XC; Yu HS; Cao Y; Liu LX; Zhang T; Wang WL; Ran JH; Liu YB; Gong W; Chen MX; Cao L; Luo Y; Wang Y; Zhou H; Yang GH; Fan J; Zhou J
Cancer Med; 2023 Feb; 12(4):4137-4146. PubMed ID: 36127767
[TBL] [Abstract][Full Text] [Related]
14. Outcomes following FGFR Inhibitor Therapy in Patients with Cholangiocarcinoma.
Gile JJ; Wookey V; Zemla TJ; Shi Q; Jin Z; Alberts SR; McWilliams RR; Ma WW; Borad M; Bekaii-Saab TS; Tran NH; Mahipal A
Target Oncol; 2022 Sep; 17(5):529-538. PubMed ID: 36056231
[TBL] [Abstract][Full Text] [Related]
15. Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma.
DiPeri TP; Zhao M; Evans KW; Varadarajan K; Moss T; Scott S; Kahle MP; Byrnes CC; Chen H; Lee SS; Halim AB; Hirai H; Wacheck V; Kwong LN; Rodon J; Javle M; Meric-Bernstam F
J Hepatol; 2024 Feb; 80(2):322-334. PubMed ID: 37972659
[TBL] [Abstract][Full Text] [Related]
16. Pemigatinib for adults with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions/rearrangements.
Walden D; Eslinger C; Bekaii-Saab T
Therap Adv Gastroenterol; 2022; 15():17562848221115317. PubMed ID: 35967919
[TBL] [Abstract][Full Text] [Related]
17. Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines.
Lacouture ME; Sibaud V; Anadkat MJ; Kaffenberger B; Leventhal J; Guindon K; Abou-Alfa G
Oncologist; 2021 Feb; 26(2):e316-e326. PubMed ID: 33021006
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of pemigatinib as a second-line treatment for advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusions in Taiwan: from the evidence of the phase II trial and the perspective of Taiwan's National Health Insurance Administration.
Chen ZR; Chueh CH; Chiang NJ; Tsai YW
Cost Eff Resour Alloc; 2023 Sep; 21(1):61. PubMed ID: 37697368
[TBL] [Abstract][Full Text] [Related]
19. Progression-Free Survival in Patients With Cholangiocarcinoma With or Without
Bibeau K; Féliz L; Lihou CF; Ren H; Abou-Alfa GK
JCO Precis Oncol; 2022 Apr; 6():e2100414. PubMed ID: 35544727
[TBL] [Abstract][Full Text] [Related]
20. Postpartum related intrahepatic cholangiocarcinoma with
Washburn L; Mahipal A; Jatoi A; Kottschade L; Tran N
J Gastrointest Oncol; 2023 Dec; 14(6):2627-2636. PubMed ID: 38196530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
